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Abstract
Background and Objective Dihydroartemisinin–piper-
aquine (DhP) is a very cost effective anti-malarial drug.
The aim of this study was to predict the budget impact of
using DhP as a first- or second-line drug to treat uncom-
plicated malaria in children in Tanzania.
Methods A dynamic Markov decision model was devel-
oped based on clinical and epidemiological data to estimate
annual cases of malaria in children aged under 5 years. The
model was used to predict the budget impact of introducing
DhP as the first- or second-line anti-malarial drug, from the
perspective of the National Malaria Control Program in
2014; thus, only the cost of drugs and diagnostics were
considered. Probabilistic sensitivity analysis was per-
formed to explore overall uncertainties in input parameters.
Results The model predicts that the policy that uses
artemether–lumefantrine (AL) and DhP as the first- and
second-line drugs (AL ? DhP), respectively, will save
about $US64,423 per year, while achieving a 3 % reduc-
tion in the number of malaria cases, compared with that of
AL ? quinine. However, the policy that uses DhP as the
first-line drug (DhP ? AL) will consume an additional
$US780,180 per year, while achieving a further 5 %
reduction in the number of malaria cases, compared with
that of AL ? DhP.
Conclusion The use of DhP as the second-line drug to
treat uncomplicated malaria in children in Tanzania is
slightly cost saving. However, the policy that uses DhP as
the first-line drug is somewhat more expensive but with
more health benefits.
Key Points for Decision Makers
Understanding the financial burden that will be
imposed by a new health technology on the health
system is important for planning and budgeting.
Dihydroartemisinin–piperaquine is relatively more
expensive than artemether–lumefantrine but has a
greater potential to reduce the burden of Plasmodium
falciparum malaria when used as the first-line drug
to treat uncomplicated malaria.
1 Introduction
Malaria is an infectious disease, usually of short duration;
there were an estimated 198 million cases of malaria
(range 124–283 million) and an estimated 584,000 deaths
(range 367,000–755,000) globally in 2013 [1]. In Tanzania,
malaria is responsible for about one-tenth of all outpatient
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fevers in children [2]. Most malaria infections in sub-Sa-
haran Africa are caused by Plasmodium falciparum, and
without adequate treatment, the disease can progress
rapidly to life-threatening severe malaria. There is a lot of
controversy surrounding the precise burden of malaria in
African countries. In 2010, malaria deaths in Tanzania
among children aged under 5 years were estimated to range
between 10,928 and 49,663 [3]. In 2013, WHO estimates
showed that there were about 14.6 million cases of sus-
pected malaria in the country, which places Tanzania
among 18 countries with the highest burden of malaria in
the sub-Saharan African region [1].
Tanzania has repeatedly changed its malaria treatment
guidelines in response to P. falciparum resistance to anti-
malarial drugs. In 2001, chloroquine was replaced with
sulfadoxine–pyrimethamine (SP) as the first-line drug to
treat uncomplicated malaria. In 2007, SP was replaced with
artemether–lumefantrine (AL), while quinine was a rec-
ommended second-line drug (AL ? quinine) [4]. In 2014,
quinine was replaced with dihydroartemisinin–piperaquine
(DhP) as the second-line drug (AL ? DhP) [5]. AL and
DhP are two of the five artemisinin-based combination
therapies (ACTs) recommended by the WHO to treat
uncomplicated malaria [6].
Recent research evidence indicates that DhP may be a
better first-line drug to treat uncomplicated malaria than
AL because it is more effective [7] and offers a prolonged
post-treatment prophylaxis, which reduces the risk of
recurrent malaria infections [8, 9]. In addition, DhP has a
simple once-a-day dosage regimen which enhances
adherence to treatment [10]. Economic evaluation studies
have also indicated that DhP is more cost effective than AL
when used as the first-line drug; hence, it represents better
value for money [8, 11, 12]. Mori et al. [12] showed that
DhP was more cost effective than AL from a providers’
perspective, with an incremental cost-effectiveness ratio of
$US12.40 per disability-adjusted life-year (DALY) averted
in a Tanzanian setting, based on a valuation performed in
December 2012 [12].
Cost-effectiveness analysis compares costs and outcomes
of competing interventions, and is an important criterion for
priority-setting decisions. However, such analyses fail to
report information that can be used to assess whether cost-
effective interventions are also affordable to the purchaser.
Budget impact analysis (BIA), which addresses the issue of
affordability, is therefore increasingly used to complement
cost-effectiveness analyses. BIA estimates the financial
consequences of adopting a new drug within a specific
healthcare setting to guide formulary listing decisions [13].
This study aims to predict the budget impact of adopting DhP
as the first- or second-line drug to treat uncomplicated
malaria in children in Tanzania compared with a previous
policy composed of AL and quinine.
2 Methods
2.1 Analytical Framework
The BIA was conducted using a dynamic Markov cohort
model with four mutually exclusive health states: ‘‘well’’,
‘‘uncomplicated malaria’’, ‘‘severe malaria’’, and ‘‘death’’
as an absorbing health state. The model is a modified
version of the one used to compare the cost effectiveness of
AL and DhP when used as the first-line drugs in Tanzania
[12]. While the original model was closed, this is an open
model, which allows entrance of new members through
births while others exit after reaching the age of more than
5 years over the 1-year time horizon of the model (Fig. 1).
The cohort begins in a ‘‘well’’ state and then transits to
other health states in 1-week cycles based on risk factors
for malaria, access to healthcare, and the effectiveness of
anti-malarial drugs.
The analysis was performed from the perspective of the
National Malaria Control Program and has a duration of
1 year. A probabilistic sensitivity analysis (PSA) was
conducted using Monte-Carlo simulations to assess the
robustness of the model considering the uncertainty asso-
ciated with the input parameters. The analysis was run
using TreeAge Pro 2015 software (TreeAge Software, Inc.,
Williamstown, PA, USA). The study adheres to the BIA
guidelines regarding principles of good practice from the
International Society for Pharmacoeconomics and Out-
come Research (ISPOR) [13].
2.2 Intervention Mix
Two competing treatment policies for uncomplicated
malaria, each consisting of AL and DhP as first- or second-
line drugs, were evaluated against a reference policy of
AL ? quinine. A regimen consisting of a 3-day dosage of
parenteral quinine, followed by an oral dose of the first-line
drug, was employed as a standard treatment for severe
malaria in all policies. The treatment policies involved are:
1. AL ? quinine: this is a reference policy, which uses
AL and quinine as first- and second-line drugs,
respectively. This policy was launched in 2006 and
followed until it was replaced in 2014 by AL ? DhP
[4].
2. AL ? DhP: this policy option substitutes quinine with
DhP as the second-line drug in the reference policy and
is consistent with the policy change of 2014 in the
country [5]. This treatment policy is also consistent
with WHO recommendations regarding the treatment
of uncomplicated malaria [6].
3. DhP ? AL: this policy uses DhP as the first-line drug
and AL as the second-line drug. This policy would
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exploit the benefits of DhP, which include relatively
higher efficacy and compliance rates. It is also
consistent with WHO recommendations regarding the
treatment of uncomplicated malaria [6].
2.3 Patient Population
The study was conducted in a sub-population of 7,273,832
children aged under 5 years in Tanzania [14]. Children are
most vulnerable to malaria and account for more than two-
thirds of all malaria deaths [1]. Estimates of the size of the
eligible population was based on a 2-week prevalence of
fevers of about 20 % [15], of which about 10.5 % have
been attributed to malaria infections [2]. The cohort grows
at a rate of about 8466 children per week, which is the
difference between the birth and aging rate [14, 16]. The
all-cause mortality rate of 81 per 1000 live births for
children aged under 5 years [17] was adjusted downward
by 11 % to account for deaths due to causes other than
malaria [18]. Progression to severe malaria and survival
rates in each arm depend on the effectiveness of the first-
and second-line drugs, which in this study are influenced
by differences in compliance rates.
2.4 Characteristics of Anti-Malarial Drugs
A large head-to-head, multicenter randomized clinical trial
indicated that DhP has a cure rate of 97.3 versus 95.5 % for
AL, based on an intention-to-treat analysis. The adminis-
tration of drugs in this trial was directly observed and
children stayed at the facilities long enough to check for
any vomiting, which implies perfect adherence to treatment
[19]. DhP is administered once daily while AL should be
taken twice daily together with fat-rich meals, both for 3
consecutive days. Compliance rates for AL and DhP range
from 60 to 80 and 70 to 90 %, respectively [10, 20].
Quinine has been used as a second-line drug for the
management of uncomplicated malaria in endemic coun-
tries for many years, mostly due to the lack of an appro-
priate alternative drug. The major limitations of quinine are
its long, three times daily dosage regimen, which extends
to 7 days, and cinchonism adverse effects. In a nested
clinical trial, quinine used as a second-line drug to treat
recurrent malaria infection in children in Uganda showed
cure rates ranging from 88 to 98 % in a head-to-head
comparison with AL and DhP [21]. An assumed compli-
ance rate varying from 40 to 60 % was used in this study,
based on a clinical trial and one other economic study [22,
23].
Patient compliance to treatment is a primary determi-
nant of therapeutic outcomes. Poor compliance to anti-
malarial drugs increases the chances of treatment failure
and, more importantly, drug resistance. However, in
economic modeling studies it is commonly assumed that
10–20 % of non-compliers to multi-dosage anti-malarial
drugs such as the ones considered in this study may
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Uncomplicated 
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Fig. 1 State transition diagram
of the model
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experience spontaneous recovery [24, 25]. Therefore, in
order to predict cure rates, we combined efficacy rates
from trial settings and adherence rates observed in routine
clinical practice using the following formula (Eq. 1):
Cure rate ¼ E0C þ Encð1  CÞ ð1Þ
where E0 is efficacy, C is the compliance rate, and Enc is
the proportion of non-compliers who may experience
spontaneous recovery.
2.5 Assumptions
The model was based on the following simplifying
assumptions:
• The policy implementation has reached a steady state.
• There is no asymptomatic malaria state; hence, all cases
of severe malaria are due to progression from uncom-
plicated malaria.
• Uncomplicated malaria is not fatal and all positive
cases in the public facilities are prescribed the recom-
mended first-line drug.
• The second-line drug ACT will be restricted in the
public sector, and when it is out of stock patients will
be given the first-line drug.
2.6 Care Seeking for Diagnosis and Treatment
of Malaria
Care-seeking behavior for the treatment of malaria is very
complex and is influenced by many factors, such as per-
ceived severity of the disease, proximity to the facility,
availability of medicine, and the ability to pay for health
services [26, 27]. In this study, caregivers are modeled to
seek care for their febrile children from three main sources:
the public sector, which also includes non-profit faith-
based facilities; the private sector, which is composed of
accredited drug shops and pharmacies; and informal sour-
ces. A recent national HIV/AIDS and Malaria Indicator
Survey reported that between 77 and 81 % of caregivers
sought care from formal health facilities [15]. Between 50
and 70 % of these formal facilities are composed of public
facilities, and the remainder include private-sector phar-
macies and drug shops, which are scattered all over the
country [28].
Between 50 and 70 % of all febrile children who visit
public facilities are treated based on malaria Rapid Diag-
nostic Test (mRDT) results and the rest are treated based
on presumptive diagnosis [29, 30]. Non-adherence by
health workers to a negative mRDT was estimated to vary
from 7 to 14 % [31, 32]. Test results were based on
Bayesian calculations, with a prior positive test probability
of 10.5 %, and sensitivity and specificity (range) of the
mRDT of 95.4 % (94.2–96.6 %) and 95.9 %
(94.8–97.0 %), respectively [33]. The sensitivity and
specificity (range) of presumptive diagnosis were set at
30 % (20–40 %) and 90 % (80–100 %), respectively [34].
Availability of the first-line drug in public facilities
varies from 40 to 80 % [35], and when it is out of stock
between 40 and 60 % of patients will be able to access it
from private-sector drug shops and pharmacies [36]. The
rest may purchase non-recommended drugs, with cure rates
ranging between 10 and 60 % [37]. If a child still has
uncomplicated malaria after the initial treatment, we
assume the caregiver will choose to return to the public
facility, where the second-line drug will be prescribed, with
availability of 80–100 % for quinine (i.e., because it is
relatively cheap) and 40–60 % for ACTs.
Private-sector drug shops and pharmacies are an
important first point of care for patients with suspected
malaria infections in Tanzania. However, diagnostic tests
are usually unavailable; hence, treatments are based on
symptoms alone. A majority of these premises stock ACTs,
following the implementation of the Affordable Medicines
Facility-malaria (AMFm) program [38]. Considering that
the major incentive of these premises is to maximize sales,
we assume that 60–80 % of febrile children receive anti-
malarial drugs [39], of which about 40–60 % are a rec-
ommended first-line drug [40]. To capture the complexity
of care seeking, we assumed that half of the patients who
fail to respond to treatments will choose to shift to the
public health facilities and the rest will remain in the pri-
vate sector.
In Tanzania, only formal healthcare facilities, including
the private-sector accredited drug shops and pharmacies,
are authorized to stock anti-malarial drugs. Therefore, all
treatments sought from informal sources such as markets,
local shops, and traditional healers are considered to be
ineffective. However, we assumed that 10–20 % of these
cases may experience spontaneous recovery [12]. Those
who continue to suffer from uncomplicated malaria will
shift to the public healthcare facilities for further treatment.
Between 3 and 7 % of untreated malaria cases, or those
who experience treatment failure, progress to severe
malaria [25, 41]. Between 80 and 100 % of severe cases of
malaria have been estimated to have access to adequate
inpatient care [42], which reduces the case-fatality rate,
ranging between 45 and 80 % [43], to about 10.9 % [44].
2.7 Resource Use and Costs
A costing study conducted at an urban district-level hos-
pital exists and this has been reported elsewhere [12].
However, due to its lack of representative cost data for
personnel and other items, the current BIA study focuses
on expenditures incurred on ACTs, mRDTs, and other
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drugs used to manage the associated co-morbidities. This is
more relevant to the National Malaria Control Program,
which is responsible for the development of malaria poli-
cies and budgeting for ACTs and mRDTs, which are lar-
gely funded by donors. For uncomplicated malaria, the
drugs included are the recommended first- and second-line
anti-malarials. We included SP also to represent the use of
non-recommended drugs, especially from the private-sec-
tor premises [15, 28]. Antipyretics such as paracetamol
were omitted because they are relatively cheap and hence
unlikely to have significant budgetary implications. For
severe malaria, the cost of a standard regimen consisting of
parenteral quinine, diclofenac, diazepam, hematinics, and a
first-line ACT was included [5].
The Global Fund’s reference prices negotiated with the
manufacturers of ACTs for children aged under 5 years in
endemic countries were used [45], while for SP a buyer
price (range) of $US0.32 ($US0.25–0.38) from the Inter-
national Drug Price Indicator Guide was used [46]. Prices
of ACTs were inflated by 20 % to account for program
costs, i.e., 10 % freight and insurance costs [46] and 10 %
as estimated local distribution costs. Prices of other drugs
were taken from the price catalogue of the Medical Stores
Department (MSD) [47]. Prices of mRDTs have decreased
recently due to price competition; hence, a unit price
(range) of $US0.45 ($US0.36–0.55) was used [30]. An
exchange rate of 1670 Tanzanian shillings to $US1 for the
year 2014 was used to convert local MSD prices into US
dollars [48].
2.8 Uncertainty
Probability distributions were employed to incorporate
uncertainties in the parameters used in the model (Table 1).
Beta distributions were used for probability parameters to
limit their possible values to the interval 0–1, while costs
were constrained between 0 to positive infinity by gamma
distributions. Normal distributions were used to describe
estimated population size, birth rates, and compliance rates
of different anti-malarial drugs. Overall uncertainty in the
parameters was propagated in the model by running a PSA
based on a Monte-Carlo simulation with 10,000 iterations.
One-way sensitivity analysis was used to test how varia-
tions in key parameters, including addition of hospitaliza-
tion costs, may potentially influence the results.
3 Results
3.1 Model Validation
The model was validated using the reference policy
(AL ? quinine) to determine whether the predicted health
outcomes from the simulations correspond with the fig-
ures reported in the literature. An estimated 10–12 million
cases of uncomplicated malaria occur in Tanzania annu-
ally, of which about two-thirds are in children aged under
5 years [30]. Our model prediction of 7,510,727 cases is
therefore consistent with the implied range of
6.7–8.0 million cases. The model predicted 173,600 cases
of severe malaria among children aged under 5 years,
which is also about two-thirds of all severe cases based on
the WHO World Malaria Report 2013 [50]. The predicted
total number of deaths in children aged under 5 years was
134,028, which is within the range of 123,100–186,700
[51]. The predicted number of malaria-attributable deaths
was 26,973, which is within the reported range of
10,928–49,663 for children aged under 5 years in Tanzania
[3].
3.2 Budget Impact Analysis
The model predicts that the treatment policy of AL ? DhP
will save about $US64,423 (0.3 %) per year, compared
with that of AL ? quinine, and the policy of DhP ? AL
will consume an additional $US780,180 (3.8 %) per year
compared with that of AL ? DhP. These represent changes
in the budget for drugs and mRDTs only (Table 2). It is
interesting to note that DhP ? AL has the highest drug
costs but the lowest costs for mRDT compared with other
policies. The reason for this difference in cost is that the
higher effectiveness rate of DhP as a first-line drug reduces
episodes of malaria and hence the requirement for mRDT.
3.3 Impact on Health Outcomes
Table 3 shows the estimated change in overall annual
health outcomes, as recommended by the new guidelines
for reporting BIA analysis [13], for the two malaria treat-
ment policies. The model predicts that the policy of
AL ? DhP has the potential to reduce the number of
malaria cases and deaths by 248,437 (3 %) and 1954
(7.2 %), respectively, compared with the reference policy
of AL ? quinine. However, the policy of DhP ? AL,
which is more expensive, has the potential to reduce the
number of malaria cases and deaths further by 364,517
(5 %) and 2868 (11.5 %), respectively, compared with the
policy of AL ? DhP.
3.4 Sensitivity Analyses
The policy of AL ? quinine has already been replaced
with that of AL ? DhP, and since it is probably not very
attractive to revert to quinine-based therapy, policy makers
will be more interested in a comparison of DhP ? AL
versus AL ? DhP. This is presented in the Tornado
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diagram shown in Fig. 2, which expresses the potential
influence of uncertain parameters on budget impact. Cost
and the compliance rates for DhP and AL were identified to
be the most influential parameters.
Considering that the cost of DhP is the most influential
parameter, it was important to show how variation in the
cost of DhP causes changes in the budget of drugs and
diagnostics, as indicated in Fig. 3. At a cost of about
Table 1 Parameters used in the model and their distributions
Parameters Estimates Distributions Sources
Cohort size of children aged under 5 years 7,273,832 ± 20 % Normal [14]
Weekly cohort growth rate 8466 ± 20 % Normal [14, 16]
Under-five mortality rate per 1000 live births 81 (72–90 %) Beta [17]
Malaria-attributed deaths in children aged under 5 years 11 % Point estimate [18]
2-Week incidences of fever episodes per child 0.20 ± 20 % Beta [15]
Percentage of febrile episodes attributed to malaria 10.5 ± 20 % Beta [2]
Case fatality rate of untreated severe malaria 60 (45–80 %) Beta [43]
Case fatality rate of treated severe malaria 10.9 % Beta [49]
Early treatment failure leads to severe malaria 5 (3–7 %) Beta [41]
Untreated malaria becomes severe 5 (3–7 %) Beta [25]
Probability of care seeking in formal facilities 79 (77–81 %) Beta [15]
Percentage of formal facilities belonging to public sector 60 (50–70 %) Beta [28]
Percentage of severe cases with access to inpatient care 90 (80–100 %) Beta [42]
Access to first-line drugs in public facilities 60 (40–80 %) Beta [35]
Access to second-line drugs in public facilities 50 (40–60 %) Beta Assumption
Percentage of children given anti-malarials in private facilities 70 (60–80 %) Beta [39]
Percentage of anti-malarials that are ACT in private facilitiesa 50 (40–60 %) Beta [36, 40]
Efficacy of DhP 97.3 (94.9–99.7 %) Beta [19]
Efficacy of AL 95.5 (93.1–97.9 %) Beta [19]
Efficacy of quinine 93.0 (88.0–98.0 %) Beta [21]
Compliance with AL 70 (60–80 %) Normal [10, 20]
Compliance with DhP 80 (70–90 %) Normal [10, 20]
Compliance with quinine 50 (40–60 %) Normal [22, 23]
Non-compliers with treatments who recover 20 (10–30 %) Beta [24, 25]
Sensitivity of mRDT 95 (94.2–96.6 %) Beta [33]
Specificity of mRDT 96 (94.8–97.0 %) Beta [33]
Sensitivity of clinical diagnosis 30 (20–40 %) Beta [34]
Specificity of clinical diagnosis 90 (80–100 %) Beta [34]
Adherence to a negative mRDT resultb 10.5 (7.0–14.0 %) Beta [31, 32]
Drugs and diagnostic costs ($US per dose/test)
DhP: Dh 40 mg, P 320 mg (‘‘3 9 1’’ pack) 0.77 (0.56–0.93) Gamma [45]
AL: A 20 mg, L 120 mg (‘‘6 9 2’’ pack) 0.67 (0.54–0.84) Gamma [45]
Quinine 300 mg/tablet 0.59 (0.47–0.70) Gamma [46]
SP: S 500 mg, pyrimethamine 25 mg (‘‘3 9 1’’ pack) 0.32 (0.25–0.38) Gamma [46]
Quinine injection 300 mg/mL (2 mL ampoule) 2.40 (1.92–2.87) Gamma [47]
Diazepam injection 5 mg/mL (2 mL ampoule) 0.23 (0.18–0.27) Gamma [47]
Diclofenac injection 25 mg/mL (3 mL ampoule) 0.29 (0.23–0.35) Gamma [47]
Dextrose 5 % (500 mL bottle) 3.95 (3.16–4.74) Gamma [47]
Ferrous sulphate ? folic acid 200 ? 0.25 mg 0.26 (0.21–0.31) Gamma [47]
Cost of mRDT 0.45 (0.36–0.55) Gamma [30]
Numbers in the parentheses represent ranges
A artemether, ACT artemisinin-based combination therapy, AL artemether–lumefantrine, Dh dihydroartemisinin, DhP dihydroartemisinin–
piperaquine, L lumefantrine, mRDT Rapid Diagnostic Test for malaria, P piperaquine, S sulfadoxine, SP sulfadoxine–pyrimethamine
a As a proportion of dispensed anti-malarial drugs
b Proportion of children who will be treated despite having a negative test result
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$US0.84 per dose of DhP, the policy of DhP ? AL is the
cheapest option and requires a total budget of about
$US20.7 million annually. It should be noted that this cost
includes 20 % program costs; hence, the actual acquisition
cost is $US0.67 per dose. That is to say, for the purpose of
cost containment, the additional budget of about
$US780,180 required by the more effective policy of
DhP ? AL may be avoided if DhP could be bought at a
price lower than $US0.67 per dose.
Table 4 shows the budget impact of including hospi-
talization costs of about $US76.46 (range $US60–90) per
patient from our previous study [12], with the assumption
that all severe cases of malaria will be treated in the public
facilities. The model predicts that the policy of AL ? DhP
will save about $US934,200 (2.9 %) per year compared
with that of AL ? quinine, and that of DhP ? AL will
save about $US500,342 (1.6 %) per year compared with
that of AL ? DhP. Therefore, the policy that uses DhP as
Table 2 Annual incremental
cost from the perspective of the
National Malaria Control
Program ($US)
Policy options mRDT costs Drug costs Total cost Incremental cost
AL ? quinine 6,350,032 14,523,023 20,873,055 Reference
AL ? DhP 6,325,074 14,483,558 20,808,632 -64,423 (0.3 %)
DhP ? AL 6,232,222 15,356,589 21,588,811 780,180 (3.8 %)
AL artemether–lumefantrine, DhP dihydroartemisinin–piperaquine, mRDT Rapid Diagnostic Test for
malaria
Table 3 Impact on the number of malaria cases and deaths for children aged under 5 years
Policy options Uncomplicated
malaria
Severe malaria All cases Incremental cases
(all)
Number of deaths Incremental deaths
AL ? quinine 7,510,727 173,599 7,684,326 Reference 26,973 Reference
AL ? DhP 7,274,872 161,016 7,435,888 -248,437 (3.2 %) 25,019 -1954 (7.2 %)
DhP ? AL 6,928,818 142,554 7,071,371 -364,517 (5.0%) 22,151 -2868 (11.5 %)
AL artemether–lumefantrine, DhP dihydroartemisinin–piperaquine
Fig. 2 Incremental Tornado
diagram of DhP ? AL vs.
AL ? DhP. AL artemether–
lumefantrine, DhP
dihydroartemisinin–
piperaquine, EV expected value
of budget impact
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the first-line drug (DhP ? AL) is the most cost-saving
treatment policy for uncomplicated malaria when hospi-
talization costs are taken into consideration.
4 Discussion
Malaria is an infectious disease, which consumes a sub-
stantial portion of the limited health budgets of sub-Saha-
ran African countries. It is the leading cause of morbidity
and mortality among outpatient visits and inpatient
admissions in Tanzania. It has been estimated that malaria
accounts for about 2 % of the gross domestic product
(GDP), which is equivalent to about 20 % of the total
health expenditure in Tanzania [52]. This is the first study
in Tanzania to estimate the budget impact of introducing
DhP to treat uncomplicated malaria in children aged under
5 years either as the first- or second-line drug.
A majority of countries in sub-Saharan Africa are using
AL as the first-line drug and quinine as second-line drug
against uncomplicated malaria. Even though ACTs are the
preferred choice for the treatment of uncomplicated
P. falciparum malaria [6], it is understandable that some
countries persist with the use of quinine as the second-line
drug due to a lack of alternative ACTs. Therefore, the
emergence of DhP as a very promising ACT has changed
the treatment dynamics of malaria in many countries in
recent years. A number of countries have already adopted
DhP as the second-line drug and many others are consid-
ering doing the same. Mainland Tanzania is one of the
countries that recently replaced quinine with DhP as a
second-line drug to treat uncomplicated malaria [5].
Several studies have shown that DhP is more cost
effective than AL to treat uncomplicated malaria in African
countries [8, 11, 12]. However, the arbitrary thresholds of
$US150 per DALY averted or 1–3 times GDP per capita,
which are commonly used to categorize interventions as
being cost effective or not, may not necessarily reflect the
willingness and ability to pay for a new intervention for
any particular country [53, 54]. In reality, a new drug can
Fig. 3 Change in total budget
of drugs and diagnostics versus
variation in the cost of
dihydroartemisinin–
piperaquine. AL artemether–
lumefantrine, DhP
dihydroartemisinin–piperaquine
Table 4 Budget impact after
including hospitalization costs
($US)
Policy options Drugs and mRDT costs Hospitalization costs Total costs Incremental costs
AL ? quinine 20,873,055 11,803,699 32,676,754 Reference
AL ? DhP 20,808,632 10,933,923 31,742,555 -934,200 (2.9 %)
DhP ? AL 21,588,811 9,653,401 31,242,212 -500,342 (1.6 %)
AL artemether–lumefantrine, DhP dihydroartemisinin–piperaquine, mRDT Rapid Diagnostic Test for
malaria
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be very cost effective but unaffordable and, for this reason,
BIA is increasingly being used to complement cost-effec-
tiveness analyses.
This study found that by considering the costs of drugs
and diagnostics only, the policy that uses DhP as the sec-
ond-line drug (AL ? DhP) to treat uncomplicated malaria
in children is slightly cost saving, i.e., $US64,423 per year,
while reducing cases of malaria by about 3 % compared
with the policy of AL ? quinine. The model also predicts
that the policy that uses DhP as the first-line drug
(DhP ? AL) increases the budget by about $US780,180
per year, while reducing the number of malaria cases by a
further 5 %, compared with AL ? DhP. Pfeil et al. [11]
found that the use of DhP as the first-line drug in moderate-
to-high transmission areas will avert 12 % of malaria cases
in children. More recently, Okell et al. [8] estimated a
reduction of 10–15 % in high-transmission areas. Our
study shows a smaller reduction in malaria cases because
we did not consider the longer prophylactic effect of DhP,
which reduces the recurrence of malaria [8, 9].
Hospitalization costs are an important component of
inpatient care costs incurred by healthcare providers to
treat severe childhood malaria. The inclusion of hospital-
ization costs in the sensitivity analysis switched the most
cost-saving treatment policy for uncomplicated malaria to
DhP ? AL, which eventually saves about $US500,342 per
year compared with AL ? DhP. Considering that the pol-
icy of DhP ? AL reduces the number of malaria cases by 5
versus 3 % with AL ? DhP, the inclusion of other outpa-
tient and inpatient costs will make DhP ? AL even more
cost saving compared with AL ? DhP.
This study has a number of limitations and, hence, its
results must be interpreted with care; more importantly, it
should never be used as the sole basis for initiating policy
change in Tanzania. Firstly, policy change is a very com-
plex and expensive undertaking [55]. In 2000, it cost the
Tanzanian Government about $US0.8 million to imple-
ment the new malaria treatment policy, representing about
4 % of total malaria expenditure and 1 % of total public
expenditure on health [56]. Another study estimated the
costs of this policy change to be equivalent to $US0.02 per
person [55].
Secondly, care-seeking behavior for diagnosis and
treatment of malaria is very complex in sub-Saharan Africa
and data may not always be readily available. In the model,
a number of structural and parameter assumptions were
made in an attempt to replicate how patients move from
one type of facility to another in actual practice when
seeking care. It is nearly impossible to model this with
sufficient accuracy. The model assumptions portray care-
givers seeking care from the informal and formal health
facilities in a very orderly manner, which rarely happens in
reality. Even the diagnosis and treatment practices in
public facilities vary from one location to another.
Thirdly, the study assumes that the majority of patients
visiting public facilities are diagnosed with mRDTs and all
positive cases are prescribed with the recommended first-line
drug, with a mean availability of 60 %. While we believe that
these are reasonable base-case assumptions, several studies
have shown that quality of care in public facilities varies
greatly and that mRDTs and drugs often completely run out
of stock for prolonged periods of time [57, 58]. The avail-
ability of a second-line drug was assumed to be restricted in
the public facilities, which may not be the case still. Dis-
pensing practice in private drug shops and pharmacies is
more complex than the way it is modeled here; hence, the
estimated health benefits of the two malaria policies may
deviate from the model predictions.
Fourthly, this study ignored the prolonged post-treat-
ment prophylactic effect of DhP, which has more potential
to prevent recurrent malaria infections than AL [8, 9]. The
model shows that an increase in the effectiveness of DhP
reduces the number of malaria cases and, hence, treatment
costs to the greatest extent when it is used as the first-line
drug. The inclusion of a prolonged prophylactic effect
would have similar implications, i.e., an increase in health
benefits and reduction in treatment costs, which would
eventually make the policy of DhP ? AL even more
attractive. Therefore, this study has underestimated the
actual benefits of the treatment policy that uses DhP as the
first-line drug.
Finally, but equally importantly, rational social planners
are concerned not only about reducing healthcare costs but
also about broader considerations when distributing scarce
healthcare resources, including considerations of efficient
and equitable healthcare.
5 Conclusion
In accordance with the present model’s predictions, the use
of DhP as the second-line drug (AL ? DhP) to treat
uncomplicated malaria in children in Tanzania is slightly
cost saving. However, the policy that uses DhP as the first-
line drug (DhP ? AL) is somewhat more expensive as it
consumes an extra $US780,180 per year, which represents
a 3.8 % increase in the budget for drugs and diagnostics,
but with more health benefits than AL ? DhP. Neverthe-
less, the use of relatively more expensive drugs such as
DhP as first-line anti-malaria drugs without proper diag-
nosis should be approached with caution. Otherwise, the
opportunity cost of presumptive treatment outweighs the
benefits due to over-diagnosis and over-treatment of
patients without clinical malaria.
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